

Work programme 2025 feedback opportunity - Cluster 1 – Health Destination 3

Fields marked with * are mandatory.

The work programme 2025 will implement the key strategic orientations set out in the [Horizon Europe strategic plan 2025-2027](#). Respondents are invited to consult the relevant cluster annexes of the strategic plan before answering the questionnaire.

Introductory questions

The feedback opportunity for the Horizon Europe work programme 2025 is carried out at the level of the 'Destinations'.

This is the survey about the **Cluster 1 – Health work programme part, Destination 3 'Tackling diseases and reducing disease burden'**.

* Have you already replied to one of the other surveys related to the Horizon Europe work programme 2025?

- Yes
- No

* 1. I am giving contribution as

- Individual, providing feedback in my personal capacity
- Representative of an academic/research organisation
- Representative of a company/business organisation
- Representative of a consumer organisation
- Representative of an environmental organisation
- Representative of a public authority
- Representative of a non-governmental organisation (NGO)
- Social partner
- Other

* 2. Your name

Tadeusz

* 3. Your surname

Hawrot

* Your email

tadeusz@parea.eu

* 5. The focus of your work is

- Global
- European
- National
- Regional and / or local

* 6. What country are you / your organisation based in?

Portugal

* 7. Name of the organisation

Please mention N/A if you reply as an individual

Psychedelic Access and Research European Alliance

* 8. What is the size of your organisation?

Please select N/A if you reply as an individual

- Less than 10 employees
- Between 11 and 50 employees
- Between 51 and 250 employees
- More than 250 employees
- N/A

* 9. What is your transparency register number?

Please mention N/A if you don't have one

163022446092-77

Questions on the orientations for work programme 2025

Please find here the orientations for the Cluster 1 – Health work programme part, Destination 3 'Tackling diseases and reducing disease burden'. The **orientations provide the impacts and outcomes** expected from the actions to be funded in 2025.

Please click the link to download the orientations

[Cluster 1 Destination 3.pdf](#)

The questions below relate to the expected impacts and outcomes as outlined in the orientations document.

1. How relevant are the expected outcomes for achieving the expected impacts described in the orientations? Please select the answer from the scale where '1' means that the expected outcome is not relevant at all, and '10' – that it is very relevant.

	1	2	3	4	5	6	7	8	9	10
Health research stakeholders, clinicians, policymakers and patients will get better understanding of diseases and disabilities, their drivers and consequences, and their relationship and links to different health determinants and conditions.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Healthcare providers, clinicians and patients will have access to advanced therapies for non-communicable diseases, supported by strategies to make them cost-effective and affordable.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Citizens and healthcare systems will benefit from better surveillance, prevention, detection, treatment and crisis management of infectious disease threats.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Healthcare providers, clinicians, regulators and patients will get access to innovative health technologies developed and validated in clinical practice, including personalised medicine approaches and use of digital tools to optimise clinical workflows.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Health research stakeholders, clinicians, policymakers, regulators and patients will benefit from the establishment of new international partnerships on brain health research and continuation of cooperation with international organisations/initiatives to combat infectious diseases, to prepare for upcoming pandemics, building resilience and to reduce burden of non-communicable diseases.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>
Policymakers will get support to evidence-based health policy-making.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

2. For the expected outcomes mentioned above, please explain why you find them relevant/not relevant.

1500 character(s) maximum

While neurology has seen a significant increase in innovative treatments (being the 2nd leading area of regulatory approvals in the last few years), the opposite is true for mental health. Innovation in mental health has stagnated for decades. In the past 3 years, the EU has approved only one new psychiatric treatment, compared to 68 in oncology. In the meantime, feelings of anxiety and depression, often coupled with persistent feelings of sadness or hopelessness, have grown to levels where virtually no one can ignore what is happening. The need for more therapeutic options is urgent and we will bend the curve only when we move from a focus on reducing symptoms to a focus on recovery. In this context, psychedelic treatments are emerging as a promising new class of treatments for mental health conditions, including addictions, as evidenced by the growing, rigorous, and compelling body of research. While the FDA is poised to approve the first psychedelic therapy for PTSD later this year in the US, the outlook for regulatory approvals and patient access in Europe is markedly more distant. Large pivotal trials are missing in Europe (all the phase III trials are taking place mostly in the US). The EU is uniquely positioned to fund more trials that could determine the safety and efficacy of psychedelic therapies, leading to their regulatory approvals, and the upcoming brain health partnership can be a perfect instrument to boost EU research in this area.

3. For the orientations presented, what is missing, should be further expanded or reformulated? Please explain why?

3000 character(s) maximum

Given the increasing burden of mental health conditions, coupled with a lack of innovation and significant unmet health and societal needs in this area, the EU should provide ample and distinct opportunities in its research calls for innovative mental health treatments, such as psychedelic therapies.

Background Documents

[Privacy_statement.pdf](#)

Contact

[Contact Form](#)